Sex differences in systemic metabolites at four life stages:cohort study with repeated metabolomics by Bell, Joshua A et al.
                          Bell, J. A., Dos Santos Ferreira, D. L., Fraser, A., Goncalves Soares,
A. L., Howe, L. D., Lawlor, D. A., Carslake, D. J., Davey Smith, G., &
O'Keeffe, L. M. (2021). Sex differences in systemic metabolites at four
life stages: cohort study with repeated metabolomics. BMC Medicine,
19, [58 (2021)].
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMC at
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-01929-2 . Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
RESEARCH ARTICLE Open Access
Sex differences in systemic metabolites at
four life stages: cohort study with repeated
metabolomics
Joshua A. Bell1,2*, Diana L. Santos Ferreira1,2, Abigail Fraser1,2, Ana Luiza G. Soares1,2, Laura D. Howe1,2,
Deborah A. Lawlor1,2,3, David Carslake1,2, George Davey Smith1,2,3 and Linda M. O’Keeffe1,2,4
Abstract
Background: Males experience higher rates of coronary heart disease (CHD) than females, but the circulating traits
underpinning this difference are poorly understood. We examined sex differences in systemic metabolites
measured at four life stages, spanning childhood to middle adulthood.
Methods: Data were from the Avon Longitudinal Study of Parents and Children (7727 offspring, 49% male; and
6500 parents, 29% male). Proton nuclear magnetic resonance (1H-NMR) spectroscopy from a targeted metabolomics
platform was performed on EDTA-plasma or serum samples to quantify 229 systemic metabolites (including
lipoprotein-subclass-specific lipids, pre-glycaemic factors, and inflammatory glycoprotein acetyls). Metabolites were
measured in the same offspring once in childhood (mean age 8 years), twice in adolescence (16 years and
18 years) and once in early adulthood (25 years), and in their parents once in middle adulthood (50 years). Linear
regression models estimated differences in metabolites for males versus females on each occasion (serial cross-
sectional associations).
Results: At 8 years, total lipids in very-low-density lipoproteins (VLDL) were lower in males; levels were higher in
males at 16 years and higher still by 18 years and 50 years (among parents) for medium-or-larger subclasses. Larger
sex differences at older ages were most pronounced for VLDL triglycerides—males had 0.19 standard deviations
(SD) (95% CI = 0.12, 0.26) higher at 18 years, 0.50 SD (95% CI = 0.42, 0.57) higher at 25 years, and 0.62 SD (95% CI =
0.55, 0.68) higher at 50 years. Low-density lipoprotein (LDL) cholesterol, apolipoprotein-B, and glycoprotein acetyls
were generally lower in males across ages. The direction and magnitude of effects were largely unchanged when
adjusting for body mass index measured at the time of metabolite assessment on each occasion.
Conclusions: Our results suggest that males begin to have higher VLDL triglyceride levels in adolescence, with
larger sex differences at older ages. Sex differences in other CHD-relevant metabolites, including LDL cholesterol,
show the opposite pattern with age, with higher levels among females. Such life course trends may inform causal
analyses with clinical endpoints in specifying traits which underpin higher age-adjusted CHD rates commonly seen
among males.
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Background
Coronary heart disease (CHD) remains the leading cause of
death globally [1, 2]. Recent decades have seen age-adjusted
incidence and mortality rates decline substantially in
higher-income countries [3], but those declines are now
slowing [4, 5] and total numbers of cases are rising in most
countries owing to population ageing and growth [2, 6].
Age-adjusted CHD rates are higher among males than fe-
males [7], and reasons for this are gaining clarity. For ex-
ample, males are known to store more fat in visceral and
ectopic compartments which drives insulin resistance [8, 9]
and results in higher type 2 diabetes rates among males
[10]. Males also have higher systolic blood pressure than fe-
males from adolescence to middle adulthood, although this
difference narrows or even reverses in older age [11–13].
Sex differences in circulating lipids are more contra-
dictory. Adult females tend to have lower triglyceride
levels compared with adult males, potentially due to hor-
monal mechanisms [14, 15], yet adult females also tend
to have higher cholesterol in low-density lipoprotein
(LDL) particles [12, 16]. Such comparisons have been
based mostly on circulating traits measured by conven-
tional clinical assays. More detailed measures from tar-
geted metabolomic platforms now exist [17] which have
helped characterise the cardiometabolic profile of preg-
nancy and menopause [18, 19]. Knowledge of sex differ-
ences in these more detailed traits at multiple life stages
may help reveal more specific circulating pathways that
underpin sex differences in age-adjusted rates of CHD,
but no such investigation has yet been conducted.
We aimed in this study to better characterise sex dif-
ferences in CHD-relevant metabolites at multiple life
stages, to help identify circulating traits that may under-
pin known sex differences in CHD burden. Using data
from a multi-generational pregnancy cohort study, we
estimated the total effect of biological sex on over 200
systemic metabolites quantified using targeted metabolo-
mics on EDTA-plasma or serum samples, including
lipoprotein subclass-specific cholesterol and triglycer-
ides, amino acids, and inflammatory glycoprotein acetyls,
at four life stages. These metabolites were measured
once in childhood (mean age 8 years), twice in adoles-
cence (16 years and 18 years), and once in early adult-
hood (25 years) on the same male and female offspring
(Generation-1 (G1)), as well as on their parents (Gener-
ation-0 (G0)) in middle adulthood (50 years). We also
examined the extent to which adiposity may mediate any
total effect of sex on metabolites by adjusting for body
mass index (BMI) at each life stage.
Methods
Study population
Data were from the Avon Longitudinal Study of Parents
and Children (ALSPAC), a population-based birth
cohort study in which 14,541 pregnant women expected
to deliver between 1 April 1991 and 31 December 1992
were recruited from the former county of Avon in
southwest England. Offspring (G1 cohort) alive at 1 year
(n = 13,988) have since been followed up with multiple
assessments with an additional 913 children enrolled
over the course of the study [20, 21]. Mothers and fa-
thers (termed hereafter as ‘partners’ as not all are
biological fathers) of offspring participants have also
been followed with multiple assessments (G0 cohort)
[22]. Parental data used here were primarily from
mothers who attended a clinic assessment between
December 2008 and July 2011 and from partners who
attended a clinic assessment between September 2011
and February 2013.
The study website contains details of all the data that
is available through a fully searchable data dictionary
and variable search tool (http://www.bristol.ac.uk/alspac/
researchers/our-data/).
Assessment of systemic metabolites
Among offspring (G1), blood samples were drawn in
clinics at mean (standard deviation, SD) ages 7.5 years
(0.3 years), 15.4 years (0.3 years), 17.7 years (0.4 years),
and 24.5 years (0.8 years). Proton nuclear magnetic res-
onance (1H-NMR) spectroscopy from a targeted meta-
bolomics platform [23] was performed on EDTA-plasma
samples from each of these four occasions to quantify
229 metabolites (149 concentrations plus 80 ratios
derived from these) including cholesterol, triglyceride,
and other lipid content in lipoprotein subclass particles
(very-low-density lipoprotein (VLDL), intermediate-
density lipoprotein (IDL), low-density lipoprotein (LDL),
high-density lipoprotein (HDL)), apolipoprotein-B and
apolipoprotein-A-1, fatty acids and amino acids, and in-
flammatory glycoprotein acetyls. Bloods at age 8 years
were taken while not fasting and bloods at age 16 years,
18 years, and 25 years were taken after a minimum of a
6-h fast (stability in these metabolite concentrations has
been shown over different fasting durations [24]).
Among parents (G0), blood samples were drawn in
clinics at mean (SD) age 47.9 years (4.5 years) among
mothers and 53.3 years (5.4 years) among partners. The
same 1H-NMR metabolomics platform used among G1
offspring was performed on serum samples taken on G0
parents after a minimum of a 6-h fast during these
clinics to quantify the same 229 metabolites described
above. Among mothers only, additional blood samples
were available from visits conducted between July 2011
and June 2013 when mothers were of mean (SD) age
50.8 years (4.4 years), from which additional measures of
the same 229 metabolites were quantified with NMR as
prior. If mothers were missing data on all metabolites on
the first measurement occasion but had data on at least
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one metabolite on the second measurement occasion,
then metabolite values from that second occasion were
used to replace missing values on the first occasion. The
number of mothers with these replacements ranged
from 215 to 223 across metabolites.
Participants eligible for analyses
To allow full use of measured data, analyses were con-
ducted using maximum numbers of participants (with N
varying across ages and between metabolites). Partici-
pants were eligible for inclusion in analyses at any age if
they had data on sex, age, and at least one of the metab-
olites. This resulted in 7727 eligible G1 offspring (3763
males, 3964 females; Fig. 1) contributing to some ana-
lyses, with sample sizes for age-specific analyses ranging
from 5403 to 5515 at age 8 years, from 3162 to 3358 at
age 16 years, from 3090 to 3174 at age 18 years, and
from 3204 to 3260 at age 25 years. The single time-point
analysis in G0 parents included 6500 eligible parents
(1855 males, 4645 females; Fig. 1), with sample sizes for
each metabolite ranging between 5800 and 6500. No
specific exclusions were made based on cardiometabolic
diagnoses or medication use in G1 or G0.
Statistical approach
We examined several characteristics of participants eli-
gible for inclusion in analyses by sex; these are described
in Additional file 1: Supplementary Methods [18, 25–
28]. These characteristics were also examined among
participants who were not eligible for inclusion in our
analyses, defined as not having data on sex, age, and ≥ 1
metabolite at any measurement occasion (6085 G1s and
7811 G0s) to examine potential for selection bias. We
additionally examined characteristics in G0 females,
G1 males and G1 females by the participation status
of G0 males (mothers’ partners), to further assess se-
lection bias.
Metabolites at each measurement occasion were stan-
dardised into SD units using z-scores (subtracting the
sex-combined mean and dividing by the sex-combined
SD). Linear regression models with robust standard er-
rors (to accommodate skewed outcome distributions)
were used to examine the mean difference and 95% con-
fidence interval (CI) for the association of sex with each
standardised metabolite on each occasion, adjusting for
age at the time of metabolite assessment. Given differ-
ences in the age of G0 parents, we centred age at 50 years
and included an interaction term between sex and
centred age to allow associations of sex with metabolites
to differ by age. Estimates are therefore interpreted as
the difference in mean (in SD units) of each metabolite
for males compared with females.
In the first set of models, no adjustments were made
for BMI or lifestyle-related factors because, although
such factors likely influence metabolites, they cannot in-
fluence biological sex (male vs female: the exposure of
Fig. 1 Selection of participants eligible for inclusion in at least one analysis
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interest) and thus cannot be confounding factors of the
total effects of sex on metabolites under study (such fac-
tors would be mediators). To examine the extent to
which adiposity may mediate any total effect of sex on
metabolites, we repeated the analyses mentioned above
with additional adjustment for BMI at the time of me-
tabolite measurement. Each BMI measure was centred
on its sex-specific mean value, and an interaction term
between sex and centred BMI was included to allow ef-
fects of sex on metabolites to differ by BMI. Condition-
ing on mediators could induce collider bias through (un)
measured confounders of the mediator-outcome associ-
ation (illustrated in Fig. 2); we considered the potential
for this bias to be low here given the strong agreement
between effect estimates of BMI with these same metab-
olites across several observational and Mendelian
randomisation analyses (i.e. low potential for mediator-
outcome confounding) [29–32].
All models were additionally run using original (non-
SD; mostly mmol/l) units to aid clinical interpretation.
Meta-regression was used to examine whether effect es-
timates change linearly with mean age on each occasion,
via P values for trend across occasions. This was applied
to directly test heterogeneity in estimates across off-
spring and parents (analysed in separate datasets) under
an independence assumption.
We performed several supplementary analyses to
examine how G0 mothers’ menopausal status and overall
sampling strategies influence results; these are described
in Additional file 1: Supplementary Methods.
Because our statistical aims involve estimation, we
present exact P values and focus on effect size and preci-
sion, as recommended [33, 34]. Analyses were conducted
using Stata 15.1 (StataCorp, College Station, TX, USA).
Results
Sample characteristics
Male and female G1s had a similar mean age on each
occasion—mean (SD) age overall was 7.5 years
(0.3 years), 15.5 years (0.3 years), 17.8 years (0.4 years),
and 24.5 years (0.8 years) successively (Table 1). A mi-
nority of males and females (each < 5.0%) were of a non-
white ethnicity. Maternal and partner education levels
were similar among male and female G1s, as was the
prevalence of maternal and partner smoking during/
around pregnancy. Mean (SD) age at peak height
Fig. 2 Illustration of the potential for collider bias in analyses of biological sex and metabolite levels when adjusting for BMI. a Estimates of the
total effect of biological sex (male vs female: exposure of interest) on metabolite levels at each time point (shown here is 8 years for example) are
not prone to confounding by BMI, socioeconomic, or behavioural factors because whilst such factors could influence metabolite levels, they
could not plausibly influence biological sex assignment at conception and would be considered mediators of effect. b Conditioning on BMI
(potential mediator) measured at the time of metabolite assessment could produce estimates of a direct effect of sex on metabolite levels at
each time point, but this could also induce non-causal associations between sex and metabolite levels due to an induced association between
sex and socioeconomic or behavioural factors (confounders of the mediator-outcome associations). Such bias may be correctable via adjustment
for confounders of the mediator-outcome association, but these could be time-varying and unmeasured. We considered the potential for collider
bias to be low here given the strong agreement between effect estimates of BMI with these same metabolites from several observational and
Mendelian randomisation analyses (i.e. low potential for mediator-outcome confounding) [29–32]
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velocity among G1s was 12.6 years (1.3 years) overall;
this was later among males than females at 13.6 years
(0.9 years) and 11.7 years (0.8 years), respectively. Based
on this, 4.5% of male and 5.7% of female G1s were post-
pubertal on the first measurement occasion (i.e. had
reached peak height prior to the 8 years clinic), while
100% of females and 97% of males were post-pubertal
on the second measurement occasion (i.e. had reached
peak height prior to the 16 years clinic).
Male G0s (partners) were on average older than female
G0s (mothers) at the time of assessment—mean (SD)
age was 53.2 years (5.3 years) among males vs 47.9 years
(4.5 years) among females (Table 1). A similarly low
proportion of males and females (each < 5.0%) was non-
white, while more males than females reported a degree
as their highest qualification (25.4% vs. 18.9% respect-
ively). Smoking during the pregnancy was more com-
mon among males than females (27.3% vs. 17.0%,
respectively). Among mothers, 62.1% were pre-
menopause by the time of clinic assessment; 19.4% were
peri-menopause and 18.6% were post-menopause.
G1s who were ineligible for any analysis had a lower
parental educational attainment than those who were
eligible and were more likely to have parents who re-
ported smoking during pregnancy (Additional file 2:
Supplementary Table 1). G0 mothers whose partner did
participate were similar to mothers whose partner did
not participate on most characteristics, but mothers
whose partner participated had a higher proportion of
degree holders and a lower proportion smoking during
pregnancy compared with mothers whose partners did
not participate (Additional file 3: Supplementary
Table 2). G1s whose mothers’ partners participated were
similar to G1s whose mothers’ partners did not partici-
pate on most characteristics, but G1s whose mothers’
partners participated were less likely to be non-white,
Table 1 Characteristics of ALSPAC G1 offspring and G0 parents eligible for analyses
G1 offspring G0 parents
Males Females Males Females
Characteristics N N N N
Age (years) on first clinic occasion—mean (SD) 3410 7.5 (0.3) 3376 7.5 (0.3) 1855 53.2 (5.3) 4645 47.9 (4.5)
Non-white ethnicity—% (N) 3328 < 5.0 (NA*) 3422 < 5.0 (NA*) 4175 < 5.0 (NA*) 4219 < 5.0 (NA*)
Highest maternal education—% (N) 3389 3470 – 4233
Certificate of secondary education 13.3 (450) 14.0 (484) – 10.2 (430)
Vocational 8.4 (286) 8.4 (293) – 7.4 (313)
Ordinary level 35.7 (1209) 34.2 (1185) – 34.3 (1453)
Advanced level 26.3 (891) 26.9 (932) – 29.3 (1238)
Degree 16.3 (553) 16.6 (576) – 18.9 (799)
Highest partner education—% (N) 3293 3378 4142 –
Certificate of secondary education 19.0 (625) 21.5 (725) 16.9 (699) –
Vocational 7.6 (251) 7.7 (259) 7.4 (308) –
Ordinary level 22.3 (734) 21.4 (723) 21.0 (869) –
Advanced level 28.1 (925) 27.4 (926) 29.3 (1213) –
Degree 23.0 (758) 22.1 (745) 25.4 (1053) –
BMI on first clinic occasion—mean (SD) 3385 16.1 (1.9) 3350 16.4 (2.2) 1831 27.5 (4.0) 4629 26.6 (5.3)
Maternal BMI pre-pregnancy—mean (SD) 3163 22.9 (3.8) 3246 22.8 (3.6) – – 3991 22.5 (3.4)
Partner BMI at pregnancy—mean (SD) 2438 25.1 (3.1) 2544 25.2 (3.3) 1493 24.7 (3.0) – –
Maternal smoking during pregnancy—% (N) 3133 22.5 (706) 3181 22.4 (713) – – 3919 17.0 (665)
Partner smoking during pregnancy—% (N) 3271 29.7 (972) 3333 31.6 (1054) 4070 27.3 (1112) –
Age (y) at peak height velocity—mean (SD) 2404 13.6 (0.9) 2688 11.7 (0.8) – – – –
Menopause status (STRAW)—% (N) – – – – – – 3513
Pre-menopause – – – 62.1 (2181)
Peri-menopause – – – 19.4 (680)
Post-menopause – – – 18.6 (652)
Participants described are those with data on sex, age, and at least 1 metabolite on any measurement occasion. ‘Maternal/partner’ characteristics refer to own
status among parents. BMI body mass index. STRAW Stages of Reproductive Age Workshop. *Cells have been censored due to small cell counts in accordance
with study ethics
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more likely to have parents with academic degrees, and
less likely to have parents who smoked during pregnancy
(Additional file 4: Supplementary Table 3). The magni-
tude of the difference by sex in these characteristics
among G1s did not differ greatly by mothers’ partner
participation status.
Sex differences in lipid metabolites
At 8 years, total lipids were lower among males than fe-
males in all lipoprotein subclasses including VLDL, IDL,
and LDL, except for HDL subclasses in which total lipids
were higher among males (Additional file 5: Supplemen-
tary Table 4; estimates in original/non-SD units in Add-
itional file 6: Supplementary Table 5). At 16 years, levels
of total lipids in (medium and larger) VLDL subclasses
were similar between the sexes, but sex differences in
these emerged at 18 years (among G1s) and were evident
at 50 years (among G0s) for subclasses that were
medium or larger—e.g. total lipids in large VLDL were
higher among males than females by 0.21 SD (95% CI =
0.14, 0.28), by 0.45 SD (95% CI = 0.37, 0.52), and by 0.72
SD (95% CI = 0.65, 0.79) at 18 years, 25 years, and
50 years, respectively. P values for trend across occasions
were generally lowest for lipids in VLDL, supporting pat-
terns of higher levels at older ages—e.g. P = 0.02 for total
lipids in large VLDL. The higher levels of VLDL lipids
seen among males at older ages were most pronounced
for triglycerides in VLDL (Fig. 3). Cholesterol was higher
among males in large VLDL particles, but lower among
males in other particles including LDL, with inconsistent
sex differences at 25 years apart from cholesterol in
HDL (Fig. 4). Sex differences in lipoprotein particle sizes
themselves were larger at older ages—appearing higher
among males for VLDL and lower among males for
HDL (Fig. 5). Apolipoprotein-B was also notably lower
among males at all ages apart from 25 years, while
apolipoprotein-B as a function of apolipoprotein-A-1
was higher among males at older ages (Fig. 5). The dir-
ection and magnitude of effects were largely unchanged
when adjusting for BMI measured at the time of metab-
olite assessment on each occasion. For example, when
adjusting for BMI, total lipids in VLDL were lower in
males by − 0.15 SD (95% CI = − 0.20, − 0.10) at 8 years
but higher in males by 0.21 SD (95% CI = 0.14, 0.28), by
0.46 SD (95% CI = 0.39, 0.53), and by 0.67 SD (95% CI =
0.61, 0.73) at 18 years, 25 years, and 50 years, respect-
ively (Additional file 7: Supplementary Table 6; estimates
in original/non-SD units in Additional file 8: Supple-
mentary Table 7).
Sex differences in pre-glycaemic and inflammatory
metabolites
Fatty acid levels tended to be lower among males than
females, with some evidence that this difference was
larger at older ages—e.g. males had lower polyunsatur-
ated fatty acids by − 0.26 SD (95% CI = − 0.32, − 0.21) at
8 years among G1s and by − 1.10 SD (95% CI = − 1.16, −
1.05) at 50 years among G0s (Fig. 6; Additional file 5:
Supplementary Table 4). Glucose was consistently higher
among male G1s, whereas among G0s at 50 years glu-
cose was − 0.24 SD (95% CI = − 0.30, − 0.17) lower
among males. Lactate and citrate levels were markedly
higher among males at 50 years, with sex differences of
0.73 SD (95% CI = 0.66, 0.79) and 1.28 SD (95% CI =
1.23, 1.32), respectively. Amino acids were consistently
higher among males after 8 years, particularly branched
chain amino acids—e.g. leucine was 0.06 SD (95% CI =
0.003, 0.11) higher among males at 8 years and 1.53 SD
(95% CI = 1.47, 1.58) higher among males at 50 years.
Comparably large sex differences were seen at 50 years
for isoleucine (1.29 SD, 95% CI = 1.23, 1.34 higher
among males) and for phenylalanine (1.44 SD, 95% CI =
1.40, 1.49 higher among males). The direction and mag-
nitude of effects were again largely unchanged when
adjusting for measured BMI at the time of metabolite as-
sessment (Additional file 7: Supplementary Table 6).
Small sex differences were seen in ketone bodies at
older ages. Creatinine was consistently higher among
males after 8 years; this difference was largest at 25 years
(1.24 SD, 95% CI = 1.18, 1.30) and was smaller at 50 years
(0.51 SD, 95% CI = 0.45, 0.56; Additional file 5: Supple-
mentary Table 4). Males had consistently lower glyco-
protein acetyls with little evidence of trend across
occasions (P = 0.62); this sex difference was smaller after
18 years (− 0.23 SD, 95% CI = − 0.29, − 0.16 at age
50 years without adjustment for BMI, and − 0.27 SD,
95% CI = − 0.33, − 0.21 with adjustment for BMI; Fig. 6).
Supplementary analyses
When comparing middle-aged males with females who
were pre-menopause, sex differences in metabolites were
similar to main estimates (Additional file 9: Supplemen-
tary Table 8; non-SD estimates in Additional file 10:
Supplementary Table 9). When comparing middle-aged
males with females who were post-menopause, sex dif-
ferences in metabolites were smaller, particularly for
VLDL lipids—e.g. total lipids in large VLDL were 0.66
SD (95% CI = 0.58, 0.73) higher among males. In con-
trast, sex differences were larger for lipids in IDL, LDL,
and HDL—e.g. total cholesterol in IDL was − 1.01 SD
(95% CI = − 1.08, − 0.95) lower among males. Sex differ-
ences were smaller for branched chain amino acids, but
were generally larger for fatty acids, glucose, and glyco-
protein acetyls—e.g. − 0.36 SD (95% CI = − 0.44, − 0.29)
lower among males for glycoprotein acetyls. The direc-
tion and magnitude of effects were again similar when
adjusting for BMI (Additional files 11 and 12: Supple-
mentary Tables 10 and 11).
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Sex differences were similar when above sets of ana-
lyses were repeated using a complete case sample of 769
G1s and 5187 G0s with data on every metabolite on
every occasion (Additional files 5, 6, 7, 8, 9, 10, 11, 12:
Supplementary Tables 4, 5, 6, 7, 8, 9, 10, 11), with ex-
pectedly lower estimate precision.
Discussion
In this study, we examined sex differences in systemic
metabolites at multiple life stages, from childhood to
middle adulthood, to help identify circulating traits that
may underpin higher age-adjusted CHD rates commonly
seen among males. Our results suggest that, from ado-
lescence onwards, lipids (particularly triglycerides) in
VLDL are higher among males while levels of other
CHD-related traits including LDL cholesterol,
apolipoprotein-B, and inflammatory glycoprotein acetyls,
are higher among females. These patterns of effect were
highly consistent when adjusting for BMI measured on
each occasion. Causal analyses of these traits in relation
to clinical endpoints are needed to understand whether
they differentially affect CHD risk among males and
females.
A causal role for LDL cholesterol in CHD aetiology is
strongly supported by human genetic [35, 36] and
pharmacological intervention [37, 38] studies. Recent
genetic evidence also supports a role of higher
apolipoprotein-B in CHD independent of LDL choles-
terol concentration [39–42]. Despite this, our results
suggest that differences in absolute levels of LDL choles-
terol or apolipoprotein-B are unlikely to underpin the
higher risk of CHD experienced among males, since
Fig. 3 Sex differences in lipoprotein triglycerides at different life stages in ALSPAC. Metabolite measures at mean age 8 years, 16 years, 18 years,
and 25 years are among ALSPAC G1 offspring; metabolite measures at mean age 50 years are among ALSPAC G0 parents (analysed separately).
Offspring models are adjusted for age at metabolite assessment; parent models are adjusted for age and age-by-sex interaction. VLDL, very-low-
density lipoprotein. IDL, intermediate-density lipoprotein. LDL, low-density lipoprotein. HDL, high-density lipoprotein
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levels were lower (more favourable) among males in
adolescence and young adulthood among G1s, as well
as in middle adulthood among G0s. However, this does
not exclude the possibility of LDL cholesterol,
apolipoprotein-B, or other metabolites which did not dif-
fer by sex in these analyses having a differential effect on
CHD among males and females; sex-stratified causal
analyses of these in relation to CHD itself are needed to
determine this. The present study aimed to estimate ab-
solute effects of sex on metabolites, not relative effects
of metabolites on CHD by sex.
In contrast, our results suggest that triglyceride con-
tent—particularly in VLDL—are higher (more adverse)
among males in adolescence and that this sex difference
is larger in young adulthood and larger still in middle
adulthood. The tendency for males to have higher
circulating triglycerides has been observed previously
[14, 15], but how differences relative to females progress
across multiple life stages has been unclear due to lack
of repeated measures. Higher triglycerides among males
at multiple life stages observed here, together with previ-
ous genetic evidence of a causal role of triglycerides for
CHD [40, 43], support triglycerides as a key target for
CHD prevention, particularly among males. Whether tri-
glycerides increase CHD risk more greatly among males
requires sex-stratified analyses.
Equally strong tendencies were found for lower HDL
cholesterol among males than females at later life stages.
However, despite robust observational associations of
lower HDL cholesterol with higher CHD risk [44], gen-
etic [35, 45] and pharmacological intervention studies
[46] do not support a causal effect of HDL cholesterol
Fig. 4 Sex differences in lipoprotein cholesterol at different life stages in ALSPAC. Metabolite measures at mean age 8 years, 16 years, 18 years,
and 25 years are among ALSPAC G1 offspring; metabolite measures at mean age 50 years are among ALSPAC G0 parents (analysed separately).
Offspring models are adjusted for age at metabolite assessment; parent models are adjusted for age and age-by-sex interaction. VLDL, very-low-
density lipoprotein. IDL, intermediate-density lipoprotein. LDL, low-density lipoprotein. HDL, high-density lipoprotein
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on CHD. Nevertheless, HDL cholesterol is increasingly
regarded as a useful non-causal marker for insulin resist-
ance and other traits that are causal, namely circulating
triglycerides, with which it tracks strongly in opposing
directions [44, 47]. The utility of HDL cholesterol as a
marker of pre-glycaemic changes is further supported by
results here showing progressively lower HDL choles-
terol levels to coincide with progressively higher
branched chain amino acid levels, which are likely com-
ponents of early-stage insulin resistance [48].
The earlier measurement occasions used in this study
(8 years and 16 years) spanned puberty for most partici-
pants—an important period of growth and development.
The mean age at puberty onset here was estimated at
13.6 years for males and 11.7 years for females based on
growth-curve modelling of repeated height measures.
This transition profoundly influences physical and sexual
maturity [49], and among females results in the release
of oestrogen and other sex hormones which are thought
to result in less adverse lipid profiles [15]; whether tes-
tosterone release among males itself results in more ad-
verse lipid profiles is less clear [15, 50]. Potential
benefits of oestrogen or harms of testosterone on lipid
profiles are supported by present results which suggest
that total lipids and triglycerides in VLDL are lower
among males before puberty, but then switch direction
after puberty onset to become higher among males in
adolescence and young adulthood, a difference which is
even greater in middle adulthood. This was also true of
cholesterol in HDL but in the reverse direction (higher
levels among males before puberty, then lower levels
after puberty). Together, this supports puberty as a piv-
otal time for the emergence of life-long sex differences
in triglycerides and risk-marking HDL cholesterol.
How these sex differences extend beyond middle age,
when the menopausal transition is complete, is less
clear. Females in middle adulthood were measured here
at mean age 47.9 years, when natural menopause has ei-
ther not yet begun or is typically in early stages. Meno-
pause status was examined here using the rigorous
STRAW criteria [18, 28], and sex differences in metabo-
lites were re-examined when including only those fe-
males who were pre-menopause; these indicated similar
results as seen when all females were included. Sex dif-
ferences were then re-examined when including only
those females who were post-menopause (also excluding
those who were peri-menopause), and sex differences in
VLDL lipids appeared narrower than were seen when all
Fig. 5 Sex differences in lipoprotein particle size and apolipoprotein concentration at different life stages in ALSPAC. Metabolite measures at
mean age 8 years, 16 years, 18 years, and 25 years are among ALSPAC G1 offspring; metabolite measures at mean age 50 years are among ALSP
AC G0 parents (analysed separately). Offspring models are adjusted for age at metabolite assessment; parent models are adjusted for age and
age-by-sex interaction. VLDL, very-low-density lipoprotein. LDL, low-density lipoprotein. HDL, high-density lipoprotein
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females were included. In contrast, sex differences in
IDL, LDL, and HDL lipids appeared wider. Differences
also appeared narrower in branched chain amino acids,
but wider in most other metabolites including fatty acids
and glucose. This suggests that proposed cardio-
protective effects of female oestrogen release [14, 15],
which would be reduced post-menopause [18, 28], are
VLDL-specific, but further studies in females with nat-
ural and surgical menopause are needed to confirm this.
Limitations
The limitations of this study include modest sample
sizes among G1s, particularly for complete case analyses,
and greater loss to follow-up among males. Unequal
numbers of males and females may result in biased esti-
mates of sex differences if loss to follow-up is related to
both sex and outcomes; however, most characteristics
were comparable between included and excluded males
and females, suggesting that such bias is unlikely or
small. Estimates were based on serial cross-sectional
associations from linear regression models which did not
account for correlation between repeated measures of
metabolites over time. In the current sample, the moder-
ate correlations between repeated measures of select me-
tabolites tended to weaken with increasing follow-up
time, e.g. the Pearson correlation between VLDL triglyc-
erides measured at 8 years and 16 years, 8 years and
18 years, and 8 years and 25 years was 0.34, 0.33, and
0.25, respectively. For LDL cholesterol, the correlations
for these same time periods were 0.61, 0.57, and 0.46;
for apolipoprotein-B, these were 0.57, 0.51, and 0.43;
and for glycoprotein acetyls, these were 0.31, 0.26, and
0.22. Mixed modelling was not presently feasible given
the volume of traits examined, the sparsity of repeated
measures for reliable non-linear modelling, and substan-
tial occasion-level variability in several metabolite ratios.
The development of a uniform approach for modelling
trajectories under such conditions will improve estimates
in future. Data were of a unique multi-generational na-
ture, comprising offspring and their parents; this opens
Fig. 6 Sex differences in fatty acids, glycolysis-related metabolites, amino acids, and glycoprotein acetyls at different life stages in ALSPAC.
Metabolite measures at mean age 8 years, 16 years, 18 years, and 25 years are among ALSPAC G1 offspring; metabolite measures at mean age
50 years are among ALSPAC G0 parents (analysed separately). Offspring models are adjusted for age at metabolite assessment; parent models are
adjusted for age and age-by-sex interaction
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the possibility of additional sources of bias from cohort
and period effects. Selection bias could also be differen-
tial between G1s and G0s. This is indicated by higher
proportions of maternal smoking among included G1s
than among included G0s who subsequently participated
in clinic assessments several years after pregnancy, indi-
cating that mothers who attended clinic assessments
were a relatively healthy subset of those initially
recruited.
We examined metabolites from a targeted NMR plat-
form which is comprised of several traits considered a
priori to be etiologically important for CHD, such as
cholesterol and triglyceride content in various non-HDL
particle types. However, this platform does not capture
other potentially important factors like insulin, sex hor-
mones, regulatory proteins, or different inflammatory
traits. Examining additional metabolites measured using
untargeted mass-spectrometry (MS) could reveal more
detailed and novel sex differences. Examining circulating
proteins from novel proteomic platforms could also be
advantageous and help identify traits which are poten-
tially more readily targetable via drugs. Such data are
not currently available at scale or with repeated mea-
sures at different life stages.
Biological sex is an essentially randomised exposure
within a causal inference framework with no expected
influence of common causes (confounders), although
such factors could influence study participation. Numer-
ous explanations exist for sex differences in metabolites
described here; these would largely be considered media-
tors. Estimates generated here therefore pertain to total
effects of sex (male vs female), rather than direct effects
of sex which are independent of potential mediating fac-
tors. In additional analyses, we adjusted for BMI mea-
sured at the time of metabolite assessment because
biological sex is known to influence BMI [7, 12] and
BMI is supported by several observational and MR stud-
ies as influencing these same metabolites [29–32]. This
adjustment did not appear to substantially attenuate ef-
fect estimates for sex, suggesting that adiposity may not
mediate/underpin the sex differences in metabolites ob-
served here. Numerous potential lifestyle-related factors
could still have mediating roles, such as adverse dietary
patterns, smoking behaviour, or alcohol consumption.
Future studies could examine these pathways using for-
mal mediation analyses; although such lifestyle-related
factors carry the added challenge of high measurement
error and variability with time, with changing prevalence
and potentially changing metabolic impacts across the
life course.
Conclusions
Measures of systemic metabolites at multiple life stages
suggest that VLDL lipids (particularly triglycerides) are
higher among males relative to females in adolescence
and that this difference is larger at older ages. In con-
trast, other CHD-related metabolites including LDL
cholesterol, apolipoprotein-B, and inflammatory glyco-
protein acetyls are higher among females in adolescence,
with similar patterns with advancing age. Such life
course trends may inform causal analyses with clinical
endpoints in specifying traits which underpin higher
age-adjusted CHD rates commonly seen among males.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12916-021-01929-2.
Additional file 1. Supplementary Methods.
Additional file 2: Supplementary Table 1. Descriptive characteristics
of ALSPAC participants eligible vs ineligible for ≥1 analysis.
Additional file 3: Supplementary Table 2. Descriptive characteristics
of participating ALSPAC mothers based on partners’ participation status.
Additional file 4: Supplementary Table 3. Descriptive characteristics
of participating ALSPAC offspring based on partners’ (of mothers)
participation status.
Additional file 5: Supplementary Table 4. Sex differences in
metabolites at different life stages among ALSPAC offspring and parents.
Additional file 6: Supplementary Table 5. Sex differences in
metabolites at different life stages among ALSPAC offspring and parents.
Additional file 7: Supplementary Table 6. Sex differences in
metabolites at different life stages among ALSPAC offspring and parents,
with BMI adjustment.
Additional file 8: Supplementary Table 7. Sex differences in
metabolites at different life stages among ALSPAC offspring and parents,
with BMI adjustment.
Additional file 9: Supplementary Table 8. Sex differences in
metabolites in middle adulthood among ALSPAC parents, with
menopausal comparisons.
Additional file 10: Supplementary Table 9. Sex differences in
metabolites in middle adulthood among ALSPAC parents, with
menopausal comparisons.
Additional file 11: Supplementary Table 10. Sex differences in
metabolites in middle adulthood among ALSPAC parents, with
menopausal comparisons and BMI adjustment.
Additional file 12: Supplementary Table 11. Sex differences in
metabolites in middle adulthood among ALSPAC parents, with
menopausal comparisons and BMI adjustment.
Acknowledgments
We are extremely grateful to the families who participated in this study, the
midwives for their help in recruiting them, and the whole ALSPAC team
which includes interviewers, computer and laboratory technicians, clerical
workers, research scientists, volunteers, managers, receptionists, and nurses.
Authors’ contributions
JAB, LMOK, and DLSF planned the study. JAB had access to data, conducted
analyses, and wrote the first draft. All authors critically reviewed manuscript
drafts and approved the final version for submission.
Funding
The UK Medical Research Council, Wellcome (102215/2/13/2 and 217065/Z/
19/Z), and the University of Bristol provide core support for ALSPAC. A
comprehensive list of grants funding is available on the ALSPAC website
(http://www.bristol.ac.uk/alspac/external/documents/grant-
acknowledgements.pdf); this research (collection of NMR metabolomics data)
was specifically funded by the MRC (MC_UU_12013/1) and NIHR (NF-SI-0611-
Bell et al. BMC Medicine           (2021) 19:58 Page 11 of 13
10196). This publication is the work of the authors who are guarantors for its
contents. JAB is supported by Cancer Research UK (C18281/A19169) and the
Elizabeth Blackwell Institute for Health Research, University of Bristol and the
Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). AF,
ALGS, and LDH are funded by UK Medical Research Council research
fellowships (MR/M009351/1 & MR/M020894/1, respectively). DAL’s
contribution to this work is supported by the European Research Council
under the European Union’s Seventh Framework Programme (FP/2007-
2013)/ERC Grant Agreement (Grant number 669545; DevelopObese), the
European Union’s Horizon 2020 research and innovation programme under
grant agreement No 733206 (LifeCycle), the United States National Institutes
of Health (NIH): National Institute of Diabetes and Digestive and Kidney
Diseases (R01 DK10324), the British Heart Foundation (AA/18/7/34219), and
National Institute of Health Research ((NF-SI-0611-10196); LMOK is supported
by a Health Research Board (HRB) of Ireland Emerging Investigator Award
(EIA-2019-007) and a UK Medical Research Council Population Health
Scientist fellowship (MR/M014509/1); DLSF, DAL, DC, and GDS work in a unit
funded by the UK Medical Research Council (MC_UU_00011/1,6) and the
University of Bristol. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
Individual-level ALSPAC data are available following an application. This
process of managed access is detailed at www.bristol.ac.uk/alspac/
researchers/access. Cohort details and data descriptions for ALSPAC are
publicly available at the same web address.
Ethics approval and consent to participate
Written informed consent was provided and ethical approval was obtained
from the ALSPAC Law and Ethics Committee and the local research ethics
committee. Consent for biological samples has been collected in accordance
with the Human Tissue Act (2004). Informed consent for the use of data
collected via questionnaires and clinics was obtained from participants





The authors declare that they have no competing interests.
Author details
1MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield
House, Bristol BS8 2BN, UK. 2Population Health Sciences, Bristol Medical
School, University of Bristol, Bristol, UK. 3Bristol NIHR Biomedical Research
Centre, Bristol, UK. 4School of Public Health, Western Gateway Building,
University College Cork, Cork, Ireland.
Received: 24 August 2020 Accepted: 27 January 2021
References
1. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al.
Global, regional, and national age-sex specific mortality for 264 causes of
death, 1980–2016: a systematic analysis for the Global Burden of Disease
Study 2016. Lancet. 2017;390(10100):1151–210.
2. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al.
Global, regional, and national burden of cardiovascular diseases for 10
causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.
3. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart
disease mortality in England and Wales between 1981 and 2000.
Circulation. 2004;109(9):1101–7.
4. Wilmot KA, O’flaherty M, Capewell S, Ford ES, Vaccarino V. Coronary heart
disease mortality declines in the United States from 1979 through 2011:
evidence for stagnation in young adults, especially women. Circulation.
2015;132(11):997–1002.
5. Sidney S, Quesenberry CP, Jaffe MG, Sorel M, Nguyen-Huynh MN, Kushi LH,
et al. Recent trends in cardiovascular mortality in the United States and
public health goals. JAMA Cardiol. 2016;1(5):594–9.
6. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al.
Demographic and epidemiologic drivers of global cardiovascular mortality.
N Engl J Med. 2015;372(14):1333–41.
7. Mosca L, Barrett-Connor E, Kass WN. Sex/gender differences in
cardiovascular disease prevention: what a difference a decade makes.
Circulation. 2011;124(19):2145–54.
8. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin
resistance and type 2 diabetes. Nature. 2006;444(7121):840–6.
9. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell.
2014;156(1):20–44.
10. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk,
pathophysiology and complications of type 2 diabetes mellitus. Endocrine
Rev. 2016;37(3):278–316.
11. Wills AK, Lawlor DA, Matthews FE, Sayer AA, Bakra E, Ben-Shlomo Y, et al.
Life course trajectories of systolic blood pressure using longitudinal data
from eight UK cohorts. PLoS Med. 2011;8(6):e1000440.
12. O’Keeffe LM, Simpkin AJ, Tilling K, Anderson EL, Hughes AD, Lawlor DA,
et al. Sex-specific trajectories of measures of cardiovascular health during
childhood and adolescence: a prospective cohort study. Atherosclerosis.
2018;278:190–6.
13. O’Keeffe LM, Simpkin AJ, Tilling K, Anderson EL, Hughes AD, Lawlor DA,
et al. Data on trajectories of measures of cardiovascular health in the Avon
Longitudinal Study of Parents and Children (ALSPAC). Data in Brief. 2019;23:
103687.
14. Link JC, Reue K. Genetic basis for sex differences in obesity and lipid
metabolism. Ann Rev Nutr. 2017;37:225–45.
15. Palmisano BT, Zhu L, Eckel RH, Stafford JM. Sex differences in lipid and
lipoprotein metabolism. Mol Metab. 2018;15:45.
16. Moran A, Jacobs DR Jr, Steinberger J, Steffen LM, Pankow JS, Hong C-P,
et al. Changes in insulin resistance and cardiovascular risk during
adolescence. Establishment of differential risk in males and females.
Circulation. 2008;117(18):2361–8.
17. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M.
Quantitative serum NMR metabolomics in large-scale epidemiology: a
primer on-omic technology. Am J Epidemiol. 2017;186(9):1084–96. https://
doi.org/10.1093/aje/kwx016.
18. Wang Q, Ferreira DLS, Nelson SM, Sattar N, Ala-Korpela M, Lawlor DA.
Metabolic characterization of menopause: cross-sectional and longitudinal
evidence. BMC Med. 2018;16(1):17.
19. Wang Q, Würtz P, Auro K, Mäkinen V-P, Kangas AJ, Soininen P, et al.
Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence.
BMC Med. 2016;14(1):205.
20. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al.
Cohort profile: the ‘children of the 90s’—the index offspring of the
Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2012;
1:111–27.
21. Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson N, et al.
The Avon Longitudinal Study of Parents and Children (ALSPAC): an update
on the enrolled sample of index children in 2019. Wellcome Open Res.
2019;4:51. https://doi.org/10.12688/wellcomeopenres.15132.1.
22. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G,
et al. Cohort profile: the Avon Longitudinal Study of Parents and Children:
ALSPAC mothers cohort. Int J Epidemiol. 2013;42(1):97–110.
23. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum
nuclear magnetic resonance metabolomics in cardiovascular epidemiology
and genetics. Circ Cardiovasc Genet. 2015;8(1):192–206.
24. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based
population: a cross-sectional study. Arch Intern Med. 2012;172(22):1707–10.
25. Cole TJ, Donaldson MD, Ben-Shlomo Y. SITAR—a useful instrument for
growth curve analysis. Int J Epidemiol. 2010;39(6):1558–66.
26. Frysz M, Howe LD, Tobias JH, Paternoster L. Using SITAR (SuperImposition by
Translation and Rotation) to estimate age at peak height velocity in Avon
Longitudinal Study of Parents and Children. Wellcome Open Res. 2018;3:90.
https://doi.org/10.12688/wellcomeopenres.14708.2.
27. Cole T, Pan H, Butler G. A mixed effects model to estimate timing and
intensity of pubertal growth from height and secondary sexual
characteristics. Ann Hum Biol. 2014;41(1):76–83.
28. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive
summary of the Stages of Reproductive Aging Workshop+ 10: addressing
the unfinished agenda of staging reproductive aging. J Clin Endocrinol
Metab. 2012;97(4):1159–68.
Bell et al. BMC Medicine           (2021) 19:58 Page 12 of 13
29. Bell JA, Carslake D, O’Keeffe LM, Frysz M, Howe LD, Hamer M, et al.
Associations of body mass and fat indexes with cardiometabolic traits. J Am
Coll Cardiol. 2018;72(24):3142–54.
30. Würtz P, Wang Q, Kangas AJ, Richmond RC, Skarp J, Tiainen M, et al.
Metabolic signatures of adiposity in young adults: Mendelian randomization
analysis and effects of weight change. PLoS Med. 2014;11(12):e1001765.
31. Bull CJ, Bell JA, Murphy N, Sanderson E, Smith GD, Timpson NJ, et al.
Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization
study. medRxiv. 2020. https://doi.org/10.1101/2020.03.19.20031138.
32. Richardson TG, Mykkanen J, Pahkala K, Ala-Korpela M, Bell JA, Taylor K, et al.
Evaluating the direct effects of childhood adiposity on adult systemic
metabolism: a multivariable Mendelian randomization analysis. medRxiv. 2020.
https://doi.org/10.1101/2020.08.25.20181412.
33. Sterne JA, Davey SG. Sifting the evidence—what’s wrong with significance
tests? BMJ. 2001;322(7280):226–31.
34. Wasserstein RL, Lazar NA. The ASA’s statement on p-values: context, process,
and purpose. Am Statistician. 2016;70(2):129–33.
35. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP,
et al. Mendelian randomization of blood lipids for coronary heart disease.
Eur Heart J. 2014;36(9):539–50.
36. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally
random allocation to lower low-density lipoprotein cholesterol on the risk
of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR,
or both: a 2× 2 factorial Mendelian randomization study. J Am Coll Cardiol.
2015;65(15):1552–61.
37. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA,
et al. Evolocumab and clinical outcomes in patients with cardiovascular
disease. N Engl J Med. 2017;376(18):1713–22.
38. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J
Med. 2015;372(25):2387–97.
39. Ference BA, Kastelein JJ, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK,
et al. Association of genetic variants related to CETP inhibitors and statins
with lipoprotein levels and cardiovascular risk. JAMA. 2017;318(10):947–56.
40. Ference BA, Kastelein JJ, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ,
et al. Association of triglyceride-lowering LPL variants and LDL-C–lowering
LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364–73.
41. Sniderman AD. Type III hyperlipoproteinemia: the forgotten, disregarded,
neglected, overlooked, ignored but highly atherogenic, and highly treatable
dyslipoproteinemia. Clin Chem. 2019;65(2):225–27. https://doi.org/10.1373/
clinchem.2018.298026.
42. Sniderman A, Couture P, De Graaf J. Diagnosis and treatment of
apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol. 2010;6(6):335.
43. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common
variants associated with plasma triglycerides and risk for coronary artery
disease. Nat Genet. 2013;45(11):1345.
44. Collaboration PS. Blood cholesterol and vascular mortality by age, sex, and
blood pressure: a meta-analysis of individual data from 61 prospective
studies with 55 000 vascular deaths. Lancet. 2007;370(9602):1829–39.
45. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M,
Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a
Mendelian randomisation study. Lancet. 2012;380(9841):572–80.
46. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al.
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N
Engl J Med. 2012;367(22):2089–99.
47. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery,
biology and clinical translation. Nat Rev Genet. 2017;18(6):331.
48. Wang Q, Holmes MV, Davey Smith G, Ala-Korpela M. Genetic support for a
causal role of insulin resistance on circulating branched-chain amino acids
and inflammation. Diab Care. 2017;40(12):1779–86. https://doi.org/10.2337/
dc17-1642.
49. Perry JR, Murray A, Day FR, Ong KK. Molecular insights into the aetiology of
female reproductive ageing. Nat Rev Endocrinol. 2015;11:725–34.
50. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F,
Mullan RJ, et al. Adverse effects of testosterone therapy in adult men: a
systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):
2560–75.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Bell et al. BMC Medicine           (2021) 19:58 Page 13 of 13
